Biopharmaceutical company Biopharma (Kyiv) has completed construction of a new pharmaceutical plant in Uzhhorod.
This was announced by Dmytro Kysilevsky, deputy chairman of the parliamentary committee on economic development.
“Biopharma Plasma has completed 80% of the construction of a plant for the production of blood plasma-based medicines in Uzhhorod. The industrial premises have already been fully built, the construction and connection of the energy infrastructure has been completed, and the installation of production equipment will begin in October,” he wrote on his Facebook page.
Kysilevsky specified that commissioning work at the plant is scheduled for late 2025-early 2026, with the launch of the first stage of production planned for the first half of 2026.
According to the plan, the volume of blood plasma-based drugs produced in Uzhhorod will be twice that of Bila Tserkva, amounting to 1.5 million liters of blood plasma per year.
Construction of the Biofarma Plasma plant in Uzhhorod began in the fall of 2024. The planned investment in the new production facility is approximately €80 million. The company’s Uzhhorod plant will focus on exports.
